Can we expect vasodilator therapy to prolong life in patients with congestive heart failure?

M. Packer, W. H. Lee, P. D. Kessler, S. S. Gottlieb

Research output: Contribution to journalArticle

Abstract

Recent evidence from the Veterans Administration Vasodilator Heart Failure Trial supports the prophylactic use of a combination of hydralazine and isosorbide dinitrate to prolong life in patients with congestive heart failure. The clinical utility of such a combination vasodilator regimen may be limited, however, by its high frequency of adverse reactions, the lack of evidence that such a regimen enhances exercise tolerance, the inconvenience of taking a large number of tablets daily for a prophylactic indication, and the dearth of clinical experience combining hydralazine-nitrate with agents that may be clinically indicated to produce long-term symptomatic benefits (i.e., converting-enzyme inhibitors). Controlled evidence in animals and uncontrolled evidence in humans suggest that converting-enzyme inhibitors may also favorably modify prognosis, perhaps by antagonizing the deleterious actions of endogenous neurohormonal systems. Trials (presently in progress) are designed to evaluate the hypothesis that converting-enzyme inhibitors exert beneficial effects on the survival of patients with congestive heart failure comparable to those reported with hydralazine and isosorbide dinitrate.

Original languageEnglish (US)
JournalJournal of Cardiovascular Pharmacology
Volume9
Issue numberSUPPL. 2
StatePublished - 1987

Fingerprint

Enzyme Inhibitors
Vasodilator Agents
Hydralazine
Heart Failure
Isosorbide Dinitrate
United States Department of Veterans Affairs
Exercise Tolerance
Nitrates
Tablets
Therapeutics
Survival

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Can we expect vasodilator therapy to prolong life in patients with congestive heart failure? / Packer, M.; Lee, W. H.; Kessler, P. D.; Gottlieb, S. S.

In: Journal of Cardiovascular Pharmacology, Vol. 9, No. SUPPL. 2, 1987.

Research output: Contribution to journalArticle

Packer, M. ; Lee, W. H. ; Kessler, P. D. ; Gottlieb, S. S. / Can we expect vasodilator therapy to prolong life in patients with congestive heart failure?. In: Journal of Cardiovascular Pharmacology. 1987 ; Vol. 9, No. SUPPL. 2.
@article{12f91fc887c6415eb415bdf4413fba54,
title = "Can we expect vasodilator therapy to prolong life in patients with congestive heart failure?",
abstract = "Recent evidence from the Veterans Administration Vasodilator Heart Failure Trial supports the prophylactic use of a combination of hydralazine and isosorbide dinitrate to prolong life in patients with congestive heart failure. The clinical utility of such a combination vasodilator regimen may be limited, however, by its high frequency of adverse reactions, the lack of evidence that such a regimen enhances exercise tolerance, the inconvenience of taking a large number of tablets daily for a prophylactic indication, and the dearth of clinical experience combining hydralazine-nitrate with agents that may be clinically indicated to produce long-term symptomatic benefits (i.e., converting-enzyme inhibitors). Controlled evidence in animals and uncontrolled evidence in humans suggest that converting-enzyme inhibitors may also favorably modify prognosis, perhaps by antagonizing the deleterious actions of endogenous neurohormonal systems. Trials (presently in progress) are designed to evaluate the hypothesis that converting-enzyme inhibitors exert beneficial effects on the survival of patients with congestive heart failure comparable to those reported with hydralazine and isosorbide dinitrate.",
author = "M. Packer and Lee, {W. H.} and Kessler, {P. D.} and Gottlieb, {S. S.}",
year = "1987",
language = "English (US)",
volume = "9",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Can we expect vasodilator therapy to prolong life in patients with congestive heart failure?

AU - Packer, M.

AU - Lee, W. H.

AU - Kessler, P. D.

AU - Gottlieb, S. S.

PY - 1987

Y1 - 1987

N2 - Recent evidence from the Veterans Administration Vasodilator Heart Failure Trial supports the prophylactic use of a combination of hydralazine and isosorbide dinitrate to prolong life in patients with congestive heart failure. The clinical utility of such a combination vasodilator regimen may be limited, however, by its high frequency of adverse reactions, the lack of evidence that such a regimen enhances exercise tolerance, the inconvenience of taking a large number of tablets daily for a prophylactic indication, and the dearth of clinical experience combining hydralazine-nitrate with agents that may be clinically indicated to produce long-term symptomatic benefits (i.e., converting-enzyme inhibitors). Controlled evidence in animals and uncontrolled evidence in humans suggest that converting-enzyme inhibitors may also favorably modify prognosis, perhaps by antagonizing the deleterious actions of endogenous neurohormonal systems. Trials (presently in progress) are designed to evaluate the hypothesis that converting-enzyme inhibitors exert beneficial effects on the survival of patients with congestive heart failure comparable to those reported with hydralazine and isosorbide dinitrate.

AB - Recent evidence from the Veterans Administration Vasodilator Heart Failure Trial supports the prophylactic use of a combination of hydralazine and isosorbide dinitrate to prolong life in patients with congestive heart failure. The clinical utility of such a combination vasodilator regimen may be limited, however, by its high frequency of adverse reactions, the lack of evidence that such a regimen enhances exercise tolerance, the inconvenience of taking a large number of tablets daily for a prophylactic indication, and the dearth of clinical experience combining hydralazine-nitrate with agents that may be clinically indicated to produce long-term symptomatic benefits (i.e., converting-enzyme inhibitors). Controlled evidence in animals and uncontrolled evidence in humans suggest that converting-enzyme inhibitors may also favorably modify prognosis, perhaps by antagonizing the deleterious actions of endogenous neurohormonal systems. Trials (presently in progress) are designed to evaluate the hypothesis that converting-enzyme inhibitors exert beneficial effects on the survival of patients with congestive heart failure comparable to those reported with hydralazine and isosorbide dinitrate.

UR - http://www.scopus.com/inward/record.url?scp=0023263102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023263102&partnerID=8YFLogxK

M3 - Article

C2 - 2441205

AN - SCOPUS:0023263102

VL - 9

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - SUPPL. 2

ER -